Track AlloVir, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

AlloVir, Inc. ALVR · Stock Open AlloVir, Inc. in new tab

9.81 USD
EPS
-1.23
P/B
0.76
ROE
-80.33
Beta
0.78
Target Price
0.98 USD
Loading chart...
Key Metrics
EPS-1.23
Book Value1.06
Price to Book0.76
Debt/Equity7.48
% Insiders49.217%
Estimates
Forward P/E-2.77
Forward EPS-0.29
Target Mean Price0.98

DCF valuation

Model fair value for AlloVir, Inc. (ALVR)
Result
Sign in to run the valuation for ALVR.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
mean target 0.98 USD (low 0.50, high 1.50)
Low 0.50
Mean 0.98
High 1.50
Price 9.81
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

AlloVir, Inc. Logo AlloVir, Inc. Analysis (ALVR)

United States Health Care Official Website Stock

Is AlloVir, Inc. a good investment? AlloVir, Inc. (ALVR) is currently trading at 9.81 USD. Market analysts have a consensus price target of 0.98 USD. This suggests the asset is currently trading above analyst expectations.

Investor FAQ

Does AlloVir, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is AlloVir, Inc.?

AlloVir, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

Company Profile

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. The company was incorporated in 2013 and is based in Waltham, Massachusetts.

Exchange Ticker
NMS (United States) ALVR
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Jan. 16, 2025 1:23
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion